Somagenetix AG Secures CHF 10 Million to Advance Gene Therapy for CGD

Somagenetix AG, a biotech company based in Zurich, announced it has raised CHF 10 million in Series A financing. This funding will advance its lentiviral gene therapy candidate, SGX-001, intended to treat Chronic Granulomatous Disease (CGD). The financing round was led by Vi Partners, with contributions from Schroders Capital, Zürcher Kantonalbank, and Verve Ventures.

The raised capital will support the clinical trial phase of SGX-001, aiming to treat the immunodeficiency disorder CGD, characterized by recurrent infections. This gene therapy could offer an alternative to stem cell transplants, which require a compatible donor. The Wyss Zurich Translational Center is backing the preclinical development.

Prof. Dr. Janine Reichenbach noted progress in their lentiviral gene therapy platform. Dr. Andrin Oswald, newly appointed CEO, emphasized the potential impact on various phagocyte-related diseases. Vi Partners expressed confidence in Somagenetix’s innovative approach to personalized medicine.